Everything you care about in one place
Follow feeds: blogs, news, RSS and more. An effortless way to read and digest content of your choice.
Get Feederinvestors.amgen.com
Amgen Inc. News Releases
Get the latest updates from Amgen Inc. News Releases directly as they happen.
Follow now 187 followers
Latest posts
Last updated 10 days ago
FDA APPROVES TEZSPIRE® FOR CHRONIC RHINOSINUSITIS WITH NASAL POLYPS
10 days ago
Approval Broadens Indication for TEZSPIRE to a Second Disease Characterized by Epithelial-Driven...
AMGEN MAKES REPATHA® AVAILABLE THROUGH AMGENNOW, A DIRECT-TO-PATIENT PROGRAM IN THE U.S.
22 days ago
Eligible Patients Can Access Repatha at Nearly 60% Discount From the List...
/C O R R E C T I O N -- Amgen/
22 days ago
In the news release, AMGEN MAKES REPATHA® AVAILABLE THROUGH AMGENNOW, A DIRECT-TO-PATIENT...
LANDMARK PHASE 3 TRIAL (VESALIUS-CV) MEETS PRIMARY ENDPOINTS IN A CARDIOVASCULAR PRIMARY PREVENTION STUDY OF 12,000 PATIENTS
26 days ago
Adding Repatha to Standard Therapy of Statins or Other LDL-C Lowering Treatments...
AMGEN ANNOUNCES $650M EXPANSION OF U.S. MANUFACTURING, CREATING HUNDREDS OF NEW JOBS
about 1 month ago
THOUSAND OAKS, Calif. , Sept. 26, 2025 /PRNewswire/ -- Amgen (NASDAQ: AMGN)...
AMGEN AND KYOWA KIRIN ANNOUNCE TOP-LINE RESULTS FROM ROCATINLIMAB PHASE 3 ASCEND LONG-TERM EXTENSION STUDY IN ADULTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS
about 2 months ago
THOUSAND OAKS, Calif. and TOKYO , Sept. 8, 2025 /PRNewswire/ -- Amgen...
AMGEN TO PRESENT AT THE MORGAN STANLEY 23RD ANNUAL GLOBAL HEALTHCARE CONFERENCE
about 2 months ago
THOUSAND OAKS, Calif. , Sept. 4, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will...
AMGEN INVESTING MORE THAN HALF A BILLION DOLLARS IN NEW, STATE-OF-THE-ART CENTER FOR SCIENCE AND INNOVATION AT U.S. GLOBAL HEADQUARTERS
about 2 months ago
Research and Development Infrastructure Investment Expected to Create Hundreds of U.S. Jobs...
AMGEN TO PRESENT AT THE 2025 WELLS FARGO HEALTHCARE CONFERENCE
about 2 months ago
THOUSAND OAKS, Calif. , Aug. 29, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will...
REPATHA® NOW INDICATED FOR ADULTS AT INCREASED RISK FOR MAJOR ADVERSE CARDIOVASCULAR EVENTS DUE TO UNCONTROLLED LDL-C
2 months ago
THOUSAND OAKS, Calif. , Aug. 25, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today...
AMGEN REPORTS SECOND QUARTER 2025 FINANCIAL RESULTS
3 months ago
THOUSAND OAKS, Calif. , Aug. 5, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today...
AMGEN ANNOUNCES 2025 THIRD QUARTER DIVIDEND
3 months ago
THOUSAND OAKS, Calif. , Aug. 1, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today...